Dose-response clarification in early drug development.
Meredith
P A
PA
University Department of Medicine and Therapeutics, Gardiner Institute, Western Infirmary, Glasgow, UK.
Elliott
H L
HL
Donnelly
R
R
Reid
J L
JL
D000959:Antihypertensive Agents / Q000493:pharmacokinetics; D001794:Blood Pressure / Q000187:drug effects; D004305:Dose-Response Relationship, Drug; D017292:Doxazosin; D004656:Enalapril / Q000493:pharmacokinetics / Q000494:pharmacology* / Q000627:therapeutic use; D006801:Humans; D006973:Hypertension / Q000188:drug therapy / Q000503:physiopathology; D009543:Nifedipine / Q000493:pharmacokinetics / Q000494:pharmacology* / Q000627:therapeutic use; D011224:Prazosin / Q000031:analogs & derivatives* / Q000493:pharmacokinetics / Q000494:pharmacology / Q000627:therapeutic use
D000959:Antihypertensive Agents; D004656:Enalapril; D009543:Nifedipine; D017292:Doxazosin; D011224:Prazosin